Global CAR-T Cell Therapy Market Report 2021 – Size, Forecasts, Trials & Trends – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2021” report has been added to ResearchAndMarkets.com’s offering.

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, an exponential increase in clinical trial activity, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion-dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta, Tecartus, and Breyanzi in treating several types of blood cancers.

Companies Mentioned

• Aleta BioTherapeutics
• Allogene Therapeutics
• Anixa Biosciences, Inc.
• Atara Biotherapeutics
• Autolus Therapeutics, plc
• Bellicum Pharmaceuticals, Inc.
• BioNTech
• bluebird bio
• Carina Biotech
• CARsgen Therapeutics
• Cartesian Therapeutics, Inc.
• CARTherics
• Celgene Corporation
• Cellectis
• Celularity, Inc.
• Celyad Oncology
• Creative Biolabs
• CRISPR Therapeutics
• Cytovia Therapeutics
• DiaCarta, Inc.
• Empirica Therapeutics
• And Many More Companies!

Trends in CAR-T Cell Therapy

CAR-T cell therapy has taken the biotech industry by storm, creating hope that it could usher in a new era of cancer treatment. However, the success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is highly competitive and is being targeted by numerous CAR-T cell therapy competitors.

Scientists, investors and developers invariably agree that the key to longer-term success in this sector depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products targeted against solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematic, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Driving Forces Impacting the CAR-T Cell Therapy Market

2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma produced Yescarta, a CAR-T therapy designed for patients with lymphoma. Approvals for these products spread like wildfire, with the EU, Canada, Australia, Japan, and other nations following suit. In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma’s brexucabtagene autoleucel, sold as Tecartus. It is the first CAR-T therapeutic to treat relapsed or refractory mantle cell lymphoma (MCL).

By February 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb company. Breyanzi is approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, from regulators, as well as the scientific and medical community at large.

For more information about this report visit https://www.researchandmarkets.com/r/vkaoyi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900